exhibit 10. 1 consultancy services agreement between neurobiological technologies, inc., 115 river road ( suite 171 ), edgewater, nj 07020 ( hereinafter referred to as “ nti ” ) and “ s & p ” pharmatest management gmbh, hasenheide 54, d - 10967 berlin ( hereinafter referred to as “ s & p ” ) content introduction nature of relationship § 1 object, scope § 2 obligations of s & p § 3 obligations of nti § 4 compensation, payments and payments schedule § 5 intellectual property § 6 confidentiality § 7 term, termination § 8 force majeure § 9 miscellaneous appendix a revised price estimation appendix b payment schedule for “ s & p ” services appendix c payment schedule of pass - through - costs for travelling and communication page 1 concerning the conduct of clinical studies ( hereinafter referred to as “ agreement ” ) between neurobiological technologies, inc., 2000 powell street, suite 800, emeryville, california 94608 and, at 115 river road ( suite 171 ), edgewater, nj 07020 ( hereinafter referred to as “ nti ” ) and “ s & p ” pharmatest management gmbh, hasenheide 54, d - 10967 berlin ( hereinafter referred to as “ s & p ” ) ( nti and s & p hereinafter together referred to as the “ parties ” and individually as a “ party ” ) introduction whereas, nti is engaged in the research, development, manufacture and future marketing of pharmaceutical products ; whereas, s & p is active in the business of consultancy services in clinical trials management, in particular in designing, setting up, projects management, site management, and monitoring relating to clinical trials ; whereas, nti wishes to retain s & p to conduct certain consultancy services on product development activities under protocol number : nti - asp - 0502 : study of acute viprinex™ for emergency stroke : a randomized, double - blind, placebo - controlled study of ancrod ( viprinex™ ) in subjects beginning treatment within 6 hours of the onset of acute, ischemic stroke ; and protocol number : nti - asp - 0503 : asp - ii ( ancrod in stroke program - ll ) : a randomized, double - blind, placebo - controlled study of ancrod (